A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Key facts
- Where
- Dresden, Duisburg, Essen, Hamburg, Köln, Leipzig, Lingen, Mainz, Mannheim, Oldenburg in Holstein, and Wangen im Allgäu, GermanySee the 13 sites
- Phase
- Phase 3
Where in Germany
- Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet DresdenDresden, GermanyTaking people
- MVZ Hausaerzte Grossenbaum GmbHDuisburg, GermanyTaking people
- InnoDiab Forschung GmbhEssen, GermanyTaking people
- Medizentrum Essen BorbeckEssen, GermanyTaking people
- Diabetes Zentrum Wilhelmsburg GbRHamburg, GermanyTaking people
- Diabeteszentrum Hamburg WestHamburg, GermanyTaking people
- Zentrum fur klinische Forschung - KölnKöln, GermanyTaking people
- Ambenet GmbH Das Ambulante BehandlungsnetzLeipzig, GermanyTaking people
- Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. SchiwietzLingen, GermanyTaking people
- BAG Drs. Med. Quist PartGMainz, GermanyTaking people
- CRS Clinical Research Services Management GmbHMannheim, GermanyTaking people
- R.E.D. Institut fuer medizinische Studien und Fortbildung GmbHOldenburg in Holstein, GermanyTaking people
- Praxis Sauter & VorbachWangen im Allgäu, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07321886EU 2025-523657-34-00
- Record updated
- 22 September 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Inclusion: Have Body Mass Index (BMI) at screening of the following:; 30 kilogram per square meter (kg/m2) OR; 27 kg/m2 with at least one of the following weight-related health conditions at screening:; high blood pressure; dyslipidemia; obstructive sleep apnea, or; heart disease; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes or type 2 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.